Novartis AG ADR (NVS)vsSight Sciences Inc (SGHT)
NVS
Novartis AG ADR
$159.90
+3.74%
HEALTHCARE · Cap: $296.54B
SGHT
Sight Sciences Inc
$5.45
-3.26%
HEALTHCARE · Cap: $309.59M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 71020% more annual revenue ($56.58B vs $79.55M). NVS leads profitability with a 23.9% profit margin vs -46.8%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
SGHT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$159.90
$68.32 premium
Margin of Safety
+30.1%
Fair Value
$7.91
Current Price
$5.45
$2.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -69.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SGHT
Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SGHT
The primary concerns for SGHT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while SGHT is a turnaround play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.40 — expect wider price swings.
SGHT is growing revenue faster at 12.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 28/100), backed by strong 23.9% margins. SGHT offers better value entry with a 30.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is a leading medical technology company dedicated to innovating the treatment of ocular diseases, particularly through advanced solutions for glaucoma management. With a strong focus on both surgical and non-surgical methods, the company boasts a diverse product portfolio complemented by a comprehensive intellectual property strategy. As the demand for minimally invasive ophthalmic therapies continues to grow, Sight Sciences is strategically positioned to capture market share and enhance patient outcomes. Its commitment to advancing eye care technology and optimizing its distribution network presents a valuable investment opportunity within the rapidly evolving healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?